Koichi Takayama

19.9k total citations · 3 hit papers
542 papers, 14.4k citations indexed

About

Koichi Takayama is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Koichi Takayama has authored 542 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 194 papers in Oncology, 169 papers in Pulmonary and Respiratory Medicine and 134 papers in Molecular Biology. Recurrent topics in Koichi Takayama's work include Lung Cancer Treatments and Mutations (113 papers), Lung Cancer Research Studies (84 papers) and Cancer Immunotherapy and Biomarkers (39 papers). Koichi Takayama is often cited by papers focused on Lung Cancer Treatments and Mutations (113 papers), Lung Cancer Research Studies (84 papers) and Cancer Immunotherapy and Biomarkers (39 papers). Koichi Takayama collaborates with scholars based in Japan, United States and Australia. Koichi Takayama's co-authors include N Qureshi, Yoichi Nakanishi, E. Ribi, Chikako Kiyohara, Nobuyuki Hara, J O Kilburn, Paolo Mascagni, Junji Uchino, Tadaaki Yamada and Taishi Harada and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Koichi Takayama

517 papers receiving 13.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

2014 525 citations Koichi Azuma, Keiichi Ota et al. profile →
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

2015 366 citations Keiichi Ota, Koichi Azuma et al. Clinical Cancer Research profile →
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

2017 308 citations Koichi Takayama, Hiroshige Yoshioka et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Koichi Takayama Japan	65	4.8k	4.5k	3.0k	2.9k	1.6k	542	14.4k
Satoshi Matsumoto Japan	55	3.5k 0.7×	2.1k 0.5×	973 0.3×	1.9k 0.7×	1.2k 0.7×	726	14.8k
Hiroshi Sakamoto Japan	71	8.8k 1.8×	3.7k 0.8×	1.5k 0.5×	2.2k 0.8×	721 0.4×	696	20.6k
Ronald G. Tompkins United States	80	8.5k 1.8×	3.4k 0.8×	3.0k 1.0×	2.1k 0.7×	6.5k 3.9×	405	30.4k
Jean‐Jacques Grob France	70	6.5k 1.4×	12.1k 2.7×	2.5k 0.8×	4.8k 1.7×	3.6k 2.2×	562	22.2k
Daniel Irimia United States	61	4.4k 0.9×	3.2k 0.7×	1.4k 0.5×	1.8k 0.6×	712 0.4×	196	16.2k
Hiroshi Hashimoto Japan	77	4.9k 1.0×	4.0k 0.9×	6.5k 2.2×	3.9k 1.4×	1.6k 1.0×	865	22.9k
Mehmet Toner United States	99	10.1k 2.1×	9.1k 2.0×	2.8k 1.0×	1.4k 0.5×	896 0.5×	457	41.1k
Feng Chen China	64	9.7k 2.0×	1.4k 0.3×	1.2k 0.4×	2.1k 0.7×	1.3k 0.8×	730	19.1k
Michael C. Fishbein United States	102	7.5k 1.6×	2.9k 0.6×	5.3k 1.8×	3.7k 1.3×	3.3k 2.0×	641	37.2k
Achim D. Gruber Germany	57	3.9k 0.8×	811 0.2×	1.7k 0.6×	2.4k 0.8×	1.4k 0.8×	322	13.4k

Countries citing papers authored by Koichi Takayama

Since Specialization

Citations

This map shows the geographic impact of Koichi Takayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koichi Takayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koichi Takayama more than expected).

Fields of papers citing papers by Koichi Takayama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koichi Takayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koichi Takayama. The network helps show where Koichi Takayama may publish in the future.

Co-authorship network of co-authors of Koichi Takayama

This figure shows the co-authorship network connecting the top 25 collaborators of Koichi Takayama. A scholar is included among the top collaborators of Koichi Takayama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koichi Takayama. Koichi Takayama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamada, Tadaaki, et al.. (2023). The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review. Translational Lung Cancer Research. 12(1). 168–180. 20 indexed citations

Kawachi, Hayato, Tadaaki Yamada, Akihiro Yoshimura, et al.. (2023). Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study). Therapeutic Advances in Medical Oncology. 15. 2621758–2621758. 1 indexed citations

Takeda, Takayuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2023). Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study. Cancers. 15(5). 1543–1543. 7 indexed citations

Iwasaku, Masahiro, Junji Uchino, Takahiro Yamada, et al.. (2023). Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial. Cancer Medicine. 12(14). 15117–15127. 3 indexed citations

Shiotsu, Shinsuke, Akihiro Yoshimura, Tadaaki Yamada, et al.. (2022). Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study. Frontiers in Oncology. 12. 904644–904644. 8 indexed citations

Matsui, Yohei, et al.. (2022). Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer. Anticancer Research. 42(10). 4921–4928. 3 indexed citations

Morimoto, Kenji, Tadaaki Yamada, Tadaaki Yamada, et al.. (2021). Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer. 161. 26–33. 39 indexed citations

Takeda, Takayuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2021). Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics. 11(12). 2170–2170. 7 indexed citations

Yoshimura, Akihiro, Tadaaki Yamada, Aya Miyagawa‐Hayashino, et al.. (2019). Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. Lung Cancer. 137. 108–112. 10 indexed citations

10.

Tanimura, Keiko, Junji Uchino, Nobuyo Tamiya, et al.. (2018). Treatment rationale and design of the RAMNITA study. Medicine. 97(23). e11084–e11084. 6 indexed citations

11.

Ota, Keiichi, Koichi Azuma, Akihiko Kawahara, et al.. (2015). Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(17). 4014–4021. 366 indexed citations breakdown →

12.

Li, Heyan, Shuo Wang, Koichi Takayama, et al.. (2015). Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Lung Cancer. 88(1). 1–8. 32 indexed citations

13.

Inoue, Hiroyuki, Chika Sakamoto, Yumiko Matsumura, et al.. (2014). TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells. Cancer Immunology Research. 2(6). 568–580. 15 indexed citations

14.

Miyamoto, Shohei, Hiroyuki Inoue, Takafumi Nakamura, et al.. (2012). Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma. Cancer Research. 72(10). 2609–2621. 188 indexed citations

15.

Uchino, Junji, Naoki Tashiro, Yūji Yoshida, et al.. (2012). Efficacy of Aprepitant in Patients with Advanced or Recurrent Lung Cancer Receiving Moderately Emetogenic Chemotherapy. Asian Pacific Journal of Cancer Prevention. 13(8). 4187–4190. 9 indexed citations

16.

Takayama, Koichi, Miiru Izumi, Taishi Harada, et al.. (2008). Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer.. PubMed. 27(6C). 4351–8. 24 indexed citations

17.

Uchino, Junji, Koichi Takayama, Akira Harada, et al.. (2007). Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. Cancer Gene Therapy. 15(2). 94–100. 18 indexed citations

18.

Kiyohara, Chikako, Kouichi Yoshimasu, Koichi Takayama, & Yoichi Nakanishi. (2005). NQO1, MPO, and the risk of lung cancer: A HuGE review. Genetics in Medicine. 7(7). 463–478. 83 indexed citations

19.

Dongen, M. E. H. van, David Smeulders, Takuya Kitamura, & Koichi Takayama. (1995). On wave phenomena in permeable foam. 81(1). 63–70. 7 indexed citations

20.

Fujita, J., et al.. (1963). RF CURRENT COMPONENT IN THE RESONANCE PROBE. National Institute for Fusion Science Repository (National Institute for Fusion Science). 19. 1–15. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact